-
First participants dosed in new POINT-HD huntingtin-lowering trial
Latest News
-
A road less traveled: how making less huntingtin can alter somatic instability and may delay symptoms
CAG repeats can get longer over time as the HD gene is used, like the growing potholes and cracks in an old road. New research finds that blocking cells from using their HTT gene slows this wear and tear, which might slow the onset of symptoms in HD.
-
EuroBuzz News: Day 2
EuroBuzz news: Day 2. Ed and Jeff reporting from the European Huntington’s Disease Network 2012 meeting in Stockholm
-
EuroBuzz News: Day 1
EuroBuzz news: Day 1. Ed and Jeff reporting from the European Huntington’s Disease Network meeting in Stockholm
-
Coming Soon: EuroBuzz 2012
Coming soon from the Euro-HD Network Meeting in Stockholm: EuroBuzz!
-
Lithium with a twist gets second chance for HD
Lithium gets a second chance in HD – with a new chemical delivery method, tested in Huntington’s disease mice
-
High-power brain scans reveal sodium changes in HD
A new brain scanning technique reveals high sodium levels in HD brains. How might this help clinical trials?
-
Mapping the neighborhood: huntingtin's new protein partners
Study of huntingtin protein's 'neighbors' reveals dozens of new drug development targets
-
Does the HD mutation affect children's growth?
A small study suggests kids with the HD mutation but no symptoms have subtle differences in growth. What does it mean
-
'Induced' stem cells make exciting advances
Stem cells from HD patients: becoming important tools for researchers – and now correcting the HD mutation in the lab
-
ASO gene silencing reaches further, lasts longer
Silencing the Huntingtin gene using ASO drugs reaches further, lasts longer and is safe. Human trial soon?
-
Phosphodiesterase inhibitors: new HD drugs entering trials soon
CHDI and Pfizer announce exciting animal work and plans for a human trial with a drug targeting 'phosphodiesterases'.
